Eli Lilly Reports Phase 2 Data for Dulaglutide in Coronary artery disease

Eli Lilly today announced Phase 2 results for dulaglutide in patients with coronary artery disease. The study demonstrated that dulaglutide achieves clinical remission compared to standard of care or placebo. These results provide important insights into the treatment of coronary artery disease and support the continued development of dulaglutide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.